Klinisk virkning og sikkerhed Vidazas virkning og sikkerhed blev undersøgt i et international, kontrolleret, open- label, randomiseret, komparativ, parallel- gruppe, fase 3- multicenterstudie (AZA PH GL 2003 CL 001) hos patienter med: intermediær- 2 og højrisiko MDS i henhold til International Prognostic Scoring System (IPSS), refraktær anæmi med overskud af blaster (RAEB), refraktær anæmi med overskud af blaster i transformation (RAEB- T) og modificeret kronisk myelomonocytleukæmi (mCMML) i henhold til French American British - (FAB -) klassifikationen.
Clinical efficacy and safety The efficacy and safety of Vidaza were studied in an international, multicenter, controlled, open-label, randomised, parallel-group, Phase 3 comparative study (AZA PH GL 2003 CL 001) in patients with: intermediate-2 and high-risk MDS according to the International Prognostic Scoring System (IPSS), refractory anaemia with excess blasts (RAEB), refractory anaemia with excess blasts in transformation (RAEB-T) and modified chronic myelomonocytic leukaemia (mCMML) according to the French American British (FAB) classification system.